Innovative Therapeutics Wesana Health is actively developing psychedelic-based therapies for mental health conditions and traumatic brain injuries, indicating an opportunity to collaborate with healthcare providers and clinics seeking cutting-edge mental health solutions.

Strategic Asset Acquisition Following the recent sale of its SANA-013 assets to Lucy Scientific Discovery, Wesana may explore new partnerships or licensing opportunities to monetize innovative assets or co-develop novel psychedelic therapies.

Research Collaborations The partnership with the University of South Carolina on the BrainStorm Lab demonstrates openness to academic collaborations, which could be expanded to engage research institutions, clinical trial providers, or biotech partners interested in neuropsychiatric treatments.

Emerging Market Potential As a publicly listed company pioneering psychedelic medicine with limited revenue streams, there is significant market opportunity among mental health clinics, wellness centers, and pharmaceutical companies seeking innovative solutions in mental health care.

Funding and Growth With $13 million in funding and a small team, Wesana is positioned for targeted growth; engaging with investors or funding sources focused on biotech or mental health innovation could facilitate further product development and commercial expansion.